Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD remibrutinib - BTK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT03926611 (CLOU064A2201) Chronic spontaneous urticaria (CSU) Phase 2 308 Change from baseline in weekly Urticaria Activity Score (UAS7) at Week 4 Arm 1 Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 2 Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 3 High dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 Arm 4 Low dose of LOU064 orally, twice daily from Day 1 to 85 Arm 5 Medium dose of LOU064 orally, twice daily from Day 1 to 85_x0 NCT04109313 (CLOU064A2201E1) Chronic spontaneous urticaria (CSU) Phase 2 250 Long-term safety and tolerability Selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 Patients with CSU who have participated in preceding studies with LOU064 Target Patients Adults with CSU inadequately controlled by H1-antihistamines Read-out Milesstone(s) H2-2021 (actual) Publication H2-2021 (EADV) 84 Investor Relations | Q3 2021 Results 2022 TBD 1 NOVARTIS | Reimagining Medicine

View entire presentation